A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

As she prepares to change medications for her MS, columnist Leigh Anne Nelson explores the U.S. government’s registry on ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...

Sanofi drug faces FDA delay following a failed late-stage trial for multiple sclerosis, with regulatory guidance expected by Q1 2024.

Dec 15 () - Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to ​a U. regulatory ...

Multiple Sclerosis Awareness Month highlights education, advocacy, research support, and ways to uplift the MS community throughout March.

IU quarterback Fernando Mendoza, a Heisman Trophy finalist, gives back to families affected by Multiple Sclerosis, raising ...